Tag Archive for: AB2 Bio

Nippon Shinyaku has secured an option to acquire exclusive US rights to commercialize AB2 Bio’s tadekinig alfa to treat primary monogenic IL-18 driven hyperinflammatory syndrome in patients with NLRC4 mutation and XIAP deficiency.